CN115835862A - 治疗阿尔茨海默病的组合及其应用 - Google Patents

治疗阿尔茨海默病的组合及其应用 Download PDF

Info

Publication number
CN115835862A
CN115835862A CN202180047687.2A CN202180047687A CN115835862A CN 115835862 A CN115835862 A CN 115835862A CN 202180047687 A CN202180047687 A CN 202180047687A CN 115835862 A CN115835862 A CN 115835862A
Authority
CN
China
Prior art keywords
disease
modafinil
alzheimer
acetaminophen
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180047687.2A
Other languages
English (en)
Inventor
孙天宇
蒋娟艳
李苌清
储结根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Xinchuangyi Biomedical Co ltd
Guangzhou Xinchuangyi Co ltd
Guangzhou Xinchuangyi Medicine Clinical Research Co ltd
Nanjing Kangfushun Pharmaceutical Co Ltd
Xiangbei Welman Pharmaceutical Co Ltd
Original Assignee
Guangzhou Xinchuangyi Biomedical Co ltd
Guangzhou Xinchuangyi Co ltd
Guangzhou Xinchuangyi Medicine Clinical Research Co ltd
Nanjing Kangfushun Pharmaceutical Co Ltd
Xiangbei Welman Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Xinchuangyi Biomedical Co ltd, Guangzhou Xinchuangyi Co ltd, Guangzhou Xinchuangyi Medicine Clinical Research Co ltd, Nanjing Kangfushun Pharmaceutical Co Ltd, Xiangbei Welman Pharmaceutical Co Ltd filed Critical Guangzhou Xinchuangyi Biomedical Co ltd
Publication of CN115835862A publication Critical patent/CN115835862A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

治疗阿尔茨海默病的组合及其应用，具体为基于莫达非尼和对乙酰氨基酚的组合及其在制备治疗阿尔茨海默病的药物中的用途。在研究中发现，将莫达非尼和对乙酰氨基酚组合治疗阿尔茨海默病时，莫达非尼的作用可被对乙酰氨基酚显著增强，试验结果表明二者组合发挥了协同作用；并且对乙酰氨基酚还消除了莫达非尼的某些不良反应，如焦虑、紧张等。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202180047687.2A 2020-07-10 2021-06-09 治疗阿尔茨海默病的组合及其应用 Pending CN115835862A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010662168 2020-07-10
CN2020106621684 2020-07-10
PCT/CN2021/099204 WO2022007578A1 (zh) 2020-07-10 2021-06-09 治疗阿尔茨海默病的组合及其应用

Publications (1)

Publication Number Publication Date
CN115835862A true CN115835862A (zh) 2023-03-21

Family

ID=79553516

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180047687.2A Pending CN115835862A (zh) 2020-07-10 2021-06-09 治疗阿尔茨海默病的组合及其应用

Country Status (2)

Country Link
CN (1) CN115835862A (zh)
WO (1) WO2022007578A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
WO2008077127A2 (en) * 2006-12-19 2008-06-26 Lavin Thomas N Use of modafinil to treat restless leg syndrome
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
CN109793734A (zh) * 2019-03-06 2019-05-24 湘北威尔曼制药股份有限公司 含有莫达非尼的组合物用于治疗抑郁症的应用

Also Published As

Publication number Publication date
WO2022007578A1 (zh) 2022-01-13

Similar Documents

Publication Publication Date Title
ES2344313T3 (es) Composiciones farmaceuticas de un esteroide neuroactivo y usos de las mismas.
EP2892518B1 (en) Compositions for treating parkinson's disease
JPH01250315A (ja) 脳機能改善剤
EA023277B1 (ru) Терапия неврологических заболеваний на основе баклофена и акампросата
KR20160067103A (ko) 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
US11234973B2 (en) Use of pridopidine for the treatment of fragile X syndrome
HUE035105T2 (en) A composition comprising nicotine and opipramole and its use
RU2768738C2 (ru) ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
WO2007054348A1 (de) Neue arzneimittel
DE69832695T2 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
CN106456637B (zh) (s)-吡吲哚及其药学上可接受的盐的药学用途
US20200093833A1 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
JP2020525480A (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
TWI659017B (zh) 吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
CN115835862A (zh) 治疗阿尔茨海默病的组合及其应用
WO2015060746A1 (ru) Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза
WO2022087176A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
KR20180068494A (ko) 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP2017518333A (ja) 神経系の変性疾患を治療及び予防するためのｐ３８及びｊｎｋ ｍａｐｋ阻害剤
AU2019273656B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
US20220313647A1 (en) Agent for treating, preventing or improving psychiatric and nervous system disorders or symptoms
JP6188784B2 (ja) 炎症性および免疫性疾患の治療のための組成物
RU2793742C2 (ru) Применение карбаматного соединения для снижения или лечения нарушений развития, включая синдром хрупкой x-хромосомы, синдром ангельмана или синдром ретта

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination